Avik Chatterjee MD, MPH

Assistant Professor, General Internal Medicine

801 Massachusetts Ave | (617) 414-7399
Avik Chatterjee
Sections

General Internal Medicine

Centers

Clinical Addiction Research and Education Unit

Evans Center for Interdisciplinary Biomedical Research

Biography

Dr. Chatterjee is a med-peds trained primary care and addiction medicine physician at several shelter-based clinics through Boston Health Care for the Homeless Program. His areas of clinical and research interest include innovative treatment models for opioid use disorder in marginalized populations, and interventions on social determinants of health, such as food insecurity. He has an additional interest in racism and health care, particularly its manifestations in medical education and training.

Education

Medicine, MD, University of North Carolina at Chapel Hill

Publications

Published on 1/23/2025

Zaragoza S, Silcox J, Rapisarda S, Summers C, Case P, To C, Chatterjee A, Walley AY, Komaromy M, Green TC. Developing a comprehensive inventory to define harm reduction housing. Harm Reduct J. 2025 Jan 23; 22(1):11. PMID: 39849487.

Published on 11/29/2024

Johnson NL, Beaugard CA, Heredia-Perez D, So-Armah K, Reason P, Yule AM, Lee CS, Chapman SE, Chatterjee A, McClay C, Weeden T, Becerril C, Thomas D, Komaromy M. Embracing anti-racism: Co-creating recommendations with Black people for how addiction treatment needs to change. Soc Sci Med. 2025 Jan; 364:117433. PMID: 39615095.

Published on 10/25/2024

Zang X, Skinner A, Li Z, Shaw LC, Behrends CN, Chatterjee A, Jalali A, Jordan AE, Morgan JR, Nolen S, Schackman BR, Marshall BDL, Walley AY. Improving racial/ethnic health equity and naloxone access among people at risk for opioid overdose: A simulation modeling analysis of community-based naloxone distribution strategies in Massachusetts, United States. Addiction. 2025 Feb; 120(2):316-326. PMID: 39450522.

Published on 10/15/2024

Zaragoza S, Silcox J, Rapisarda S, Summers C, Case P, To C, Chatterjee A, Walley A, Komaromy M, Green T. Developing a Comprehensive Inventory to Define Harm Reduction Housing. Res Sq. 2024 Oct 15. PMID: 39483918.

Published on 10/11/2024

Beaugard CA, Johnson NL, Heredia-Perez D, Chapman SE, Chatterjee A, Lee CS, McClay C, Reason P, Thomas D, Weeden T, Yule AM, So-Armah K, Komaromy M. The Effect of Racial Concordance for Black Patients in Addiction Treatment: A Scoping Review of the Literature. Subst Use Addctn J. 2025 Jan; 46(1):103-111. PMID: 39394669.

Published on 10/1/2024

Chatterjee A, Stewart EA, Assoumou SA, Chrysanthopoulou SA, Zwick H, Harris RA, O'Dea R, Schackman BR, White LF, Linas BP. Health and Economic Outcomes of Offering Buprenorphine in Homeless Shelters in Massachusetts. JAMA Netw Open. 2024 Oct 01; 7(10):e2437233. PMID: 39412807.

Published on 9/17/2024

Dunleavy S, Douchee J, Liu T, Johnson NL, Komaromy M, Chatterjee A. Racism, not race: Quantitative analysis of the use of race and racism in the addiction literature. Soc Sci Med. 2024 Nov; 360:117325. PMID: 39293285.

Published on 9/17/2024

Castry M, Tin Y, Feder NM, Lewis N, Chatterjee A, Rudorf M, Samet JH, Beers D, Medley B, Gilbert L, Linas BP, Barocas JA. An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder. J Subst Use Addict Treat. 2024 Dec; 167:209517. PMID: 39299504.

Published on 8/22/2024

Ascunce Gonzalez K, Swartz N, Linares MA, GelpĂ­-Acosta C, Chatterjee A. Latine perspectives on the impact of family, perceptions of medication, health systems, incarceration, and housing on accessing opioid agonist therapy: A thematic analysis. J Subst Use Addict Treat. 2024 Dec; 167:209491. PMID: 39179210.

Published on 8/1/2024

Xuan Z, Walley AY, Yan S, Chatterjee A, Green TG, Pollini RA. Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time. JAMA Netw Open. 2024 Aug 01; 7(8):e2427236. PMID: 39207758.

View full list of 63 publications.